InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,909.23
(
0.03%
)
Post# of 112719
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

whoswho

Send PM Follow Ignore
Followers 0
Posts 198
Boards Moderated 0
Alias Born 01/04/2005

whoswho

Member Level

Re: bbotcs post# 89277

Monday, 07/26/2021 7:24:00 PM

Monday, July 26, 2021 7:24:00 PM

Post# of 112719
EYEG
Eyegate Pharmaceuticals (NASDAQ:EYEG) shares are trading higher Monday afternoon after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 million.
Bayon Therapeutics is an ophthalmic specialty pharmaceutical company. 
Eyegate also announced the appointment of Brian M. Strem as President and CEO. Strem is a Co-Founder and Managing Director of Bayon Therapeutics.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States.
At the time of publication, shares were trading 103.8% higher at $6.36. The stock has a 52-week high of $8.18 and a 52-week low of $3.11. 

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up